Heparin trọng lượng phân tử thấp được liều trị trong suy thận: một khảo sát quốc gia

Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP et al (2019) ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J 54(3) Garcia DA, Baglin TP, Weitz JI, Samama MM (2012) Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e24S-e43S Scottish Intercollegiate Guidelines Network (SIGN) (2010) Prevention and management of venous thromboembolism Edinburgh: SIGN (SIGN publication no. 122) Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B et al (2013) International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 11(1):56–70 Witt DM, Nieuwlaat R, Clark NP, Ansell J, Holbrook A, Skov J et al (2018) American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv 2(22):3257–3291 Blazing MA, de Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D et al (2004) Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 292(1):55–64 Cohen M, Blaber R, Demers C, Gurfinkel EP, Langer A, Fromell G et al (1997) The essence trial: efficacy and safety of subcutaneous enoxaparin in unstable angina and non-Q-wave MI: a double-blind, randomized, parallel-group, multicenter study comparing enoxaparin and intravenous unfractionated heparin: methods and design. J Thromb Thrombolysis 4(2):271–274 Daskalopoulos ME, Daskalopoulou SS, Tzortzis E, Sfiridis P, Nikolaou A, Dimitroulis D et al (2005) Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. Eur J Vasc Endovasc Surg 29(6):638–650 Hull RD, Raskob GE, Brant RF, Pineo GF, Elliott G, Stein PD et al (2000) Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med 160(2):229–36 Jolly SS, Faxon DP, Fox KA, Afzal R, Boden WE, Widimsky P et al (2009) Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. J Am Coll Cardiol 54(5):468–476 Karthaus M, Kretzschmar A, Kröning H, Biakhov M, Irwin D, Marschner N et al (2006) Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 17(2):289–296 Luomanmäki K, Grankvist S, Hallert C, Jauro I, Ketola K, Kim HC et al (1996) A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. J Intern Med 240(2):85–92 Ramacciotti E, Araújo GR, Lastoria S, Maffei FH, Karaoglan de Moura L, Michaelis W et al (2004) An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis. Thromb Res 114(3):149–53 Sabatine MS, Morrow DA, Dalby A, Pfisterer M, Duris T, Lopez-Sendon J et al (2007) Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel. J Am Coll Cardiol 49(23):2256–2263 White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K et al (2006) Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J 152(6):1042–1050 Baglin T, Barrowcliffe TW, Cohen A, Greaves M (2006) Guidelines on the use and monitoring of heparin. Br J Haematol 133(1):19–34 Lim W, Dentali F, Eikelboom JW, Crowther MA (2006) Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 144(9):673–684 Park D, Southern W, Calvo M, Kushnir M, Solorzano C, Sinnet M et al (2016) Treatment with dalteparin is associated with a lower risk of bleeding compared to treatment with unfractionated heparin in patients with renal insufficiency. J Gen Intern Med 31(2):182–187 Trujillo-Santos J, Schellong S, Falga C, Zorrilla V, Gallego P, Barrón M et al (2013) Low-molecular-weight or unfractionated heparin in venous thromboembolism: the influence of renal function. Am J Med 126(5):425–34.e1 Crowther M, Lim W (2016) Use of low molecular weight heparins in patients with renal failure; time to re-evaluate our preconceptions. J Gen Intern Med 31(2):147–148 Nederlandse federatie van Nefrologie (NfN) (2012) Richtlijn Antistolling met laagmoleculairgewicht heparines (LMWH) bij nierinsufficiëntie [in Dutch]. Nieuwegein, the Netherlands: NfN Dutch Internists Association (NVI) (2021) Richtlijn antitrombotisch beleid. Behandeling LMWH bij nierfunctiestoornissen en risico op VTE [in Dutch]. Utrecht: Dutch Internists Association Royal Dutch Pharmacists Assciation (KNMP) (2021) DALTEPARINE NIERFUNCTIE. KNMP. [cited 2021–06–28]. Available from: https://kennisbank.knmp.nl Royal Dutch Pharmacists Assciation (KNMP) (2021) NADROPARINE NIERFUNCTIE. KNMP [cited 2021–06–28]. Available from: https://kennisbank.knmp.nl Royal Dutch Pharmacists Assciation (KNMP) (2021) ENOXAPARIN NIERFUNCTIE. KNMP [cited 2021–06–28]. Available from: https://kennisbank.knmp.nl Royal Dutch Pharmacists Assciation (KNMP) (2021) TINZAPARINE NIERFUNCTIE. KNMP [cited 2021–06–28]. Available from: https://kennisbank.knmp.nl Ashley C, Dunleavy A (2014) The renal drug handbook. 4 ed. London: CRC Press 276, 367, 1002 IBM Micromedex (2021) Enoxaparin sodium. In: Dose adjustments. IBM Corporation. [cited 2021–06–28]. Available from: www.micromedexsolutions.com IBM Micromedex (2021) Nadroparin. In: Dose adjustments. IBM Corporation. [cited 2021–06–28]. Available from: https://www.micromedexsolutions.com IBM Micromedex (2021) Dalteparin sodium. In: Dose adjustments. IBM Corporation. [cited 2021–06–28]. Available from: https://www.micromedexsolutions.com IBM Micromedex (2021) Tinzaparin Sodium. In: Dose adjustments. IBM Corporation. [cited 2021–06–28]. Available from: https://www.micromedexsolutions.com Hull RD (2021) Suggested dose adjustments of low molecular weight (LMW) heparins in adults with renal insufficiency. Waltham, MA: UpToDate [cited 2021–02–25]. Available from: https://www.uptodate.com Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, Kher A, Aiach M, Fiessinger JN (1994) Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group Thromb Haemost 71(6):698–702 Bara L, Leizorovicz A, Picolet H, Samama M (1992) Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either Logiparin (LMWH) or unfractionated heparin. Post-surgery Logiparin Study Group Thromb Res 65(4–5):641–650 Hornung P, Khairoun M, Dekker FW, Kaasjager KAH, Huisman A, Jakulj L et al (2020) Dosage reduction of low weight heparin in patients with renal dysfunction: effects on anti-Xa levels and clinical outcomes. PLoS ONE 15(10):e0239222 Falgá C, Capdevila JA, Soler S, Rabuñal R, Sánchez Muñoz-Torrero JF, Gallego P et al (2007) Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry. Thromb Haemost 98(4):771–6 Prandoni P, Lensing AW, Büller HR, Carta M, Cogo A, Vigo M et al (1992) Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 339(8791):441–445 Walenga JM, Hoppensteadt D, Fareed J (1991) Laboratory monitoring of the clinical effects of low molecular weight heparins. Thromb Res Suppl 14:49–62 Lin A, Vazquez SR, Jones AE, Witt DM (2019) Description of anti-Xa monitoring practices during low molecular weight heparin use. J Thromb Thrombolysis 48(4):623–628 Thomas O, Lybeck E, Strandberg K, Tynngård N, Schött U (2015) Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays. PLoS ONE 10(1):e0116835 Olie RH, Meertens NEL, Henskens YMC, Ten Cate H (2017) Empirically reduced dosages of tinzaparin in patients with moderate-to-severe renal insufficiency lead to inadequate anti-Xa levels. Nephron 137(2):113–123 Russcher M, Josephus Jitta N, Kraaijenhagen RJ, Fijnheer R, Pasker-de Jong PC, Gaillard CA (2013) Preemptive dosage reduction of nadroparin in patients with renal failure: a retrospective case series. Clin Kidney J 6(5):473–477 Shprecher AR, Cheng-Lai A, Madsen EM, Cohen HW, Sinnett MJ, Wong ST et al (2005) Peak antifactor xa activity produced by dalteparin treatment in patients with renal impairment compared with controls. Pharmacotherapy 25(6):817–822 Smit R, Marum RJ Van, Péquériaux NCV, Hollander AAMJ, Bleeker MWP, Hermens WAJJ et al (2016) Prevalentie van correcte anti-Xa-bloedspiegels bij patiënten met verminderde nierfunctie op basis van dosisadvies conform richtlijn Nederlandse Federatie voor Nefrologie. Dutch Platform for Pharmaceutical Research (NPFO). [cited 2021–06–28] van Bergen EDP, Huisman A, Welsing PMJ, de Winter MA, Rookmaaker MB, Kaasjager HAH et al (2019) Dalteparin and anti-Xa: a complex interplay of therapeutic drug monitoring. Neth J Med 77(10):360–365 Ojik AL van, Hemmelder M, Hoogendoorn M, Folkeringa R, Smit R, Derijks HJ et al (2016) Anti-Xa-activiteit van therapeutisch nadroparine bij verminderde nierfunctie en behandeling conform richtlijn Nederlandse federatie voor Nefrologie: vergelijking met standaarddosis bij normale nierfunctie. Dutch Platform for Pharmaceutical Research (NPFO). [cited 2021–06–28] Mylan Healthcare BV (2021) Fraxiparine 9.500IE/1ml oplossing voor injectie. Samenvatting van de productkenmerken. [cited 2022–03–03]. Available from: geneesmiddeleninformatiebank.nl Pfizer (2015) Fragmin oplossing voor injectie. Samenvatting van de productkenmerken. [cited 2022–03–03]. Available from: geneesmiddeleninformatiebank.nl Techdow Pharma Netherlands BV (2021) Inhixa 2.000 IE (20 mg)/0,2 ml oplossing voor injectie in een voorgevulde spuit. Samenvatting van de productkenmerken. [cited 2022–03–03]. Available from: geneesmiddeleninformatiebank.nl Leo Pharma BV (2019) Innohep oplossing voor injectie. Samenvatting van de productkenmerken. [cited 2022–03–03]. Available from: geneesmiddeleninformatiebank.nl National Institute for Public Health and the Environment (RIVM) (2021) Algemene en academische ziekenhuizen. In: Locaties. In: Regionaal & Internationaal. In: Ziekenhuiszorg. RIVM. [cited 2021–06–28]. Available from: https://www.volksgezondheidenzorg.info/onderwerp/ziekenhuiszorg/regionaal-internationaal/locaties#node-algemene-en-academische-ziekenhuizen Cooperating Top Clinical Training hospitals (STZ) (2021) Het STZ topklinisch zorgregister. Bureau STZ. [cited 2021–06–28]. Available from: https://www.stz.nl/30160/topklinisch-zorgregister Johansen KB, Balchen T (2013) Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance?. Exp Hematol Oncol 2:21 Hetzel GR, Sucker C (2005) The heparins: all a nephrologist should know. Nephrol Dial Transplant 20(10):2036–2042